Ronald M. Bukowski – författare

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

​​​The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.​

​​

​The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.

Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.​

​​​The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.​

Distinguished physicians and researchers from prestigious Cancer Centers around the world offer their expertise in current and innovative management of cancer in the spine. These authors bring together the latest thinking from diverse fields of medicine to provide, in one volume, a guide to coordinated management of all aspects of spinal tumors covering chemo- and radiation therapy, pain management, diagnostic radiology, as well as reconstructive surgery and palliative care. Highlights include management of vertebral metastases, innovations in radiotherapy, treatment of pathological fractures, curative strategies for primary malignancies, as well as a guide to pain management and end-of-life care.

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Clinical Management of Renal Tumors provides an in-depth review of the data relating to the management of renal tumors as well as an updated description regarding pathologic and molecular classification of renal tumors. The neoplasms covered include clear cell carcinomas, papillary cancers, nonepithelial tumors, and other mass lesions that resemble tumors. The management of patients with renal cancer having localized or advanced disease are discussed. Surgical approaches for primary and metastatic tumors, symptom palliation, and systemic therapy for metastatic disease including immunotherapy and targeted approaches are discussed in detail.

Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Currently the functions of the VHL protein are being investigated, and the biology of clear cell carcinoma of the kidney is under study. Additionally, papillary carcinomas of the kidney appear to express different molecular defects, and these are now being unraveled.

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients'' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Distinguished physicians and researchers from prestigious Cancer Centers around the world offer their expertise in current and innovative management of cancer in the spine. These authors bring together the latest thinking from diverse fields of medicine to provide, in one volume, a guide to coordinated management of all aspects of spinal tumors covering chemo- and radiation therapy, pain management, diagnostic radiology, as well as reconstructive surgery and palliative care. Highlights include management of vertebral metastases, innovations in radiotherapy, treatment of pathological fractures, curative strategies for primary malignancies, as well as a guide to pain management and end-of-life care.

Distinguished physicians and researchers from prestigious Cancer Centers around the world offer their expertise in current and innovative management of cancer in the spine. These authors bring together the latest thinking from diverse fields of medicine to provide, in one volume, a guide to coordinated management of all aspects of spinal tumors covering chemo- and radiation therapy, pain management, diagnostic radiology, as well as reconstructive surgery and palliative care. Highlights include management of vertebral metastases, innovations in radiotherapy, treatment of pathological fractures, curative strategies for primary malignancies, as well as a guide to pain management and end-of-life care.

Advanced renal cell carcinoma is resistant to nearly all forms of systematic therapy. For this reason the last decade has seen numerous research groups working on immunotherapeutic strategies. "Immunotherapy of Renal Cell Carcinoma" reports the contributions of most of the world's leading research groups to two international conferences on the immunobiology of this illness. 16 chapters divided into experimental and clinical studies provide an overview of immunotherapy in renal cell carcinoma and a discussion of new laboratory approaches to this topic. The scope of subjects ranges from basic studies of oncogenes and MDRI gene expression, experimental metastases, radio-immunoconjugates, TIL-and LAK-cells, monoclonal antibodies to clinical trials with Interferon, Tumour Necrosis Factor and Interleukin-2. This book will be of interest to clinicians and researchers working in the areas of urology, pathology, medical oncology and radiotherapy. For basic scientists it will be a source of information on clinical aspects of this disease; for clinicians it will provide a review of the current achievements of basic research in the field of immunology and immunotherapy of renal cell carcinoma.